J&J’s Erleada Gives Chase To Xtandi For Non-Metastatic Prostate Cancer With Approval In Europe

 
• By Jo Shorthouse

Astellas/Pfizer’s Xtandi and Johnson & Johnson’s Erleada are both now approved for non-metastatic castration-resistant prostate cancer in Europe, while Xtandi benefits from physician familiarity, Erleada has shown greater metastasis-free survival.

SpartanHelmet
Data from Janssen's SPARTAN trial meant EU approval for Erleada • Source: Shutterstock

More from Anticancer

More from Therapy Areas